Biohaven (BHVN) Non-Current Assets (2021 - 2026)
Biohaven (BHVN) posted Non-Current Assets of $80.8 million for Q1 2026, down 2.84% sequentially from $83.1 million in Q4 2025, and up 6.0% YoY from $76.2 million in Q1 2025.
Biohaven (BHVN) Non-Current Assets (2021 - 2026) Analysis & Trends
Biohaven has reported Non-Current Assets for 6 years, with the latest figure at $80.8 million in Q1 2026.
- Quarterly Non-Current Assets rose 6.0% year-over-year to $80.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $325.0 million (up 10.45% YoY) and the FY2025 annual result came in at $83.1 million, up 8.46% from the prior year.
- Non-Current Assets retreated to $80.8 million in Q1 2026 per BHVN's latest filing, from $83.1 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $85.5 million in Q3 2025 and troughed at $55.1 million in Q3 2022.
- A 5-year average of $73.9 million and a median of $74.0 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets surged 58.38% in 2022, then declined 5.75% in 2024.
- Over 5 years, Non-Current Assets stood at $74.8 million in 2022, then fell by 5.41% to $70.8 million in 2023, then rose by 8.29% to $76.6 million in 2024, then advanced by 8.46% to $83.1 million in 2025, then fell by 2.84% to $80.8 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $80.8 million, $83.1 million, and $85.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Biohaven | 2.21 Bn | 1.94 Bn | - | 74.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 74.18 Mn |
| Mar 31, 2026 | 80.76 Mn |
| Dec 31, 2025 | 83.12 Mn |
| Sep 30, 2025 | 85.51 Mn |
| Jun 30, 2025 | 75.59 Mn |
| Mar 31, 2025 | 76.19 Mn |
| Dec 31, 2024 | 76.64 Mn |
| Sep 30, 2024 | 70.02 Mn |
| Jun 30, 2024 | 71.37 Mn |
| Mar 31, 2024 | 69.79 Mn |
| Dec 31, 2023 | 70.77 Mn |
| Sep 30, 2023 | 72.17 Mn |
| Jun 30, 2023 | 72.62 Mn |
| Mar 31, 2023 | 74.05 Mn |
| Dec 31, 2022 | 74.82 Mn |
| Sep 30, 2022 | 55.10 Mn |
| Dec 31, 2021 | 47.24 Mn |